ID
45494
Beschrijving
Principal Investigator: Levi Garraway, M.D. Ph.D, Dana Farber Cancer Institute, Boston, MA USA; Broad Institute, Cambridge, MA USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000447 Prostate cancer is a prevalent cause of cancer morbidity and mortality in men. In order to characterize the full range of somatic mutations in protein-coding genes that may drive the growth of prostate cancer, we sequenced the exonic regions of genomic and tumor DNA from over 100 patients with high-risk primary prostate cancer. Using hybrid capture and paired end DNA sequencing, we identified mutations in several novel putative prostate cancer genes. We interrogated copy number changes across tumor genomes using high-density SNP arrays, and identified a molecular subtype of cancer characterized by mutation of the ubiquitin ligase subunit SPOP and copy number loss at specific genomic loci.
Link
Trefwoorden
Versies (2)
- 24-10-22 24-10-22 - Simon Heim
- 13-12-22 13-12-22 - Kristina Keller
Houder van rechten
Levi Garraway, M.D. Ph.D, Dana Farber Cancer Institute, Boston, MA USA; Broad Institute, Cambridge, MA USA
Geüploaded op
13 december 2022
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000447 Prostate Cancer Genome Sequencing Project
Subject ID, age at onset, gender, primary diagnosis, cancer stage, PSA level, and radiation therapy of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, subject source ID, and consent groups of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Subject ID, age at onset, gender, primary diagnosis, cancer stage, PSA level, and radiation therapy of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Sample ID, analyte type [somatic or genomic DNA, total RNA], sample type [tumor or normal], type of material, body site where sample was collected, anatomical zone of the prostate from which sample derived, tumor grade, RNA integrity number of RNA sample, Gleason Score, fusion status of TMPRSS2-ERG gene of participant tumor, and percent of tumor specimen with grade 4 or 5 histology of samples obtained from participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
Similar models
Subject ID, age at onset, gender, primary diagnosis, cancer stage, PSA level, and radiation therapy of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, subject source ID, and consent groups of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Sample ID, subject ID, sample source, sample source ID, and sample use variables obtained from participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Subject ID, age at onset, gender, primary diagnosis, cancer stage, PSA level, and radiation therapy of participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
- Sample ID, analyte type [somatic or genomic DNA, total RNA], sample type [tumor or normal], type of material, body site where sample was collected, anatomical zone of the prostate from which sample derived, tumor grade, RNA integrity number of RNA sample, Gleason Score, fusion status of TMPRSS2-ERG gene of participant tumor, and percent of tumor specimen with grade 4 or 5 histology of samples obtained from participants with prostate cancer and involved in the "Prostate Cancer Genome Sequencing Project" project.
C2348585 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,2])
C3854607 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,2])
C4761063 (UMLS CUI [1,3])
C1522449 (UMLS CUI [1,2])